NCT02537379 - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection | Biotech Hunter

Enrollment

552

Participants

Timeline

Start Date

September 15, 2015

Primary Completion Date

June 5, 2017

Study Completion Date

June 5, 2017

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF

SOF 400 mg tablets administered orally once daily

DRUG

COPE

COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)

Trial Locations (45)

Unknown

Amagasaki-shi

Asahi-shi

Asahikawa-shi

Beppu-shi

Chichibu-shi

Fujioka-shi

Fukui-shi

Hamamatsu

Iizuka-shi

Inzai-shi

Ishinomaki-shi

Iwaki

Izunokuni-shi

Kahoku-gun

Kanazawa

Kirishima-shi

Kisarazu-shi

Kitamoto-shi

Kobe

Koshigaya-shi

Kure-shi

Moriguchi-shi

Nagakute-shi

Nagaoka-shi

Nagasaki

Nagoya

Nakagami-gun

Nanto-shi

Nishinomiya-shi

Ofukeshi

Okayama

Ome-shi

Osaka

Ōta-ku

Sapporo

Sasebo-Shi

Sendai

Shinagawa-ku

Shinjuku-ku

Tokorozawa-shi

Tokushima

Wakayama

Yachiyo-shi

Yokohama

Yufu-shi